NCT05427487View on ClinicalTrials.gov

Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours

PHASE1RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

February 17, 2023

Primary Completion Date

September 30, 2026

Study Completion Date

November 30, 2026

Conditions
Colorectal CancerGastric CancerOvarian Cancer
Interventions
BIOLOGICAL

IVX037

Bioselected oncolytic RNA virus

BIOLOGICAL

Sintilimab

An immune checkpoint inhibitor

Trial Locations (3)

2000

RECRUITING

Sydney site, Sydney

3000

RECRUITING

Melbourne Site, Melbourne

5000

RECRUITING

South Australia site, Adelaide

All Listed Sponsors
collaborator

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

lead

ImmVirx Pty Ltd

INDUSTRY